Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole and Rifampin on Vemurafenib PK
NCT02608034Phase 1Completed
- Sponsor
- Genentech
- Start
- May 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of vemurafenib in melanoma (2 arms), sponsored by Genentech. Primary endpoints: Area under the concentration-time curve From Time 0 to 12 Hours Postdose, Maximum observed concentration at Day 20 and 1 more. Started May 2016; status: completed.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02608034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608034.